AOTMiT: Changes to drug programs at next Transparency Council meeting

The agenda includes:

1 Prepare an opinion on the inclusion in reimbursement of drugs containing the active substance rituximab in the indication resulting from changes in the provisions of the drug program.

2 Prepare an opinion on the inclusion in reimbursement of drugs containing the active substance tocilizumab in the indication resulting from changes in the provisions of the drug program.

3 Prepare an opinion on the evaluation of changes in the provisions of drug program B.75 related to the treatment of vasculitis.

4 Prepare a position paper on the examination of the legitimacy of issuing approvals for reimbursement of the medicinal product Daraprim (pyrimethamine) for the indications: congenital toxoplasmosis, ocular toxoplasmosis, central nervous system toxoplasmosis in the course of HIV infection.

5 Prepare an opinion on the continuation of coverage of medicines containing the active substance valganciclovirum in indications: cytomegalovirus infections after organ or bone marrow transplantation-treatment; Epstein-Barr virus infections after organ or bone marrow transplantation-treatment.

6. Prepare an opinion on the continuation of the inclusion in reimbursement of drugs containing the active substance doxazosinum in the indications: chronic kidney disease in children under 18 years of age; neurogenic bladder dysfunction in children under 18 years of age; non-neurogenic bladder dysfunction in children under 18 years of age.

7 Prepare an opinion on the continuation of coverage of medicines containing the active substance doxazosinum in the indication: chronic kidney disease in children under 18 years of age.

Source: AOTMiT